Maternal serum cancer antigen 125: A marker of severity of Preeclampsia

Gottipati Geya, Kantharaju Supriya

Research output: Contribution to journalArticle

Abstract

Aim: The aim of this study is to study the levels of cancer antigen 125 (CA-125) in normal, preeclampsia, and gestational hypertension study groups and correlate with other parameters which mark the severity of the disease. Materials and methods: A cross-sectional study was conducted at a Tertiary Care Hospital, Mangaluru, India. A total of 165 subjects were divided into three study groups: preeclampsia, gestational hypertension, and normal pregnancy, and each group consisted of 55 subjects. CA-125 levels were measured in these study groups. Results: The mean value of CA-125 in the preeclampsia group was 56.7 IU/mL which was significantly higher compared with other two study groups. CA-125 was found to have a positive correlation with systolic blood pressure (BP) (r value = 0.4, p value = 0.001), diastolic BP (r value = 0.3, p value = 0.001), and uric acid (r value = 0.2, p value = 0.001) and also an association was observed between increasing CA-125 and proteinuria (p value = 0.001) oligohydramnios (p value = 0.001) fetal growth restriction (p value = 0.03) and onset of the disease (p value = 0.001). However, a negative correlation with platelets (r value = −0.14, p value = 0.06) and birth weight (r value = −0.113, p value = 0.15) was observed. Conclusion: CA-125 is a marker indicating increasing severity of the disease. It is a biochemical marker which can be used in the screening of preeclampsia. Further studies are needed for the evaluation of raising serial CA-125 levels as a marker of progression of the disease. Clinical significance: Hypertensive disorders of pregnancy are one of the most common causes of death due to pregnancy. CA-125 was proposed to be elevated in patients with hypertension due to chronic inflammation. Hence, CA-125 levels if used as a screening tool can estimate the severity of the disease and help clinicians in identifying women who are at risk for further complications and act accordingly.

Original languageEnglish
Pages (from-to)100-102
Number of pages3
JournalJournal of SAFOG
Volume11
Issue number2
DOIs
Publication statusPublished - 01-03-2019
Externally publishedYes

Fingerprint

Pre-Eclampsia
Mothers
Antigens
Serum
Neoplasms
Blood Pressure
Pregnancy Induced Hypertension
Pregnancy
Oligohydramnios
Tertiary Healthcare
Fetal Development
Uric Acid
Proteinuria
Tertiary Care Centers
Birth Weight
Disease Progression
India
Cause of Death
Blood Platelets
Cross-Sectional Studies

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynaecology

Cite this

Geya, Gottipati ; Supriya, Kantharaju. / Maternal serum cancer antigen 125 : A marker of severity of Preeclampsia. In: Journal of SAFOG. 2019 ; Vol. 11, No. 2. pp. 100-102.
@article{237f931dacb446748f6f478cee1423eb,
title = "Maternal serum cancer antigen 125: A marker of severity of Preeclampsia",
abstract = "Aim: The aim of this study is to study the levels of cancer antigen 125 (CA-125) in normal, preeclampsia, and gestational hypertension study groups and correlate with other parameters which mark the severity of the disease. Materials and methods: A cross-sectional study was conducted at a Tertiary Care Hospital, Mangaluru, India. A total of 165 subjects were divided into three study groups: preeclampsia, gestational hypertension, and normal pregnancy, and each group consisted of 55 subjects. CA-125 levels were measured in these study groups. Results: The mean value of CA-125 in the preeclampsia group was 56.7 IU/mL which was significantly higher compared with other two study groups. CA-125 was found to have a positive correlation with systolic blood pressure (BP) (r value = 0.4, p value = 0.001), diastolic BP (r value = 0.3, p value = 0.001), and uric acid (r value = 0.2, p value = 0.001) and also an association was observed between increasing CA-125 and proteinuria (p value = 0.001) oligohydramnios (p value = 0.001) fetal growth restriction (p value = 0.03) and onset of the disease (p value = 0.001). However, a negative correlation with platelets (r value = −0.14, p value = 0.06) and birth weight (r value = −0.113, p value = 0.15) was observed. Conclusion: CA-125 is a marker indicating increasing severity of the disease. It is a biochemical marker which can be used in the screening of preeclampsia. Further studies are needed for the evaluation of raising serial CA-125 levels as a marker of progression of the disease. Clinical significance: Hypertensive disorders of pregnancy are one of the most common causes of death due to pregnancy. CA-125 was proposed to be elevated in patients with hypertension due to chronic inflammation. Hence, CA-125 levels if used as a screening tool can estimate the severity of the disease and help clinicians in identifying women who are at risk for further complications and act accordingly.",
author = "Gottipati Geya and Kantharaju Supriya",
year = "2019",
month = "3",
day = "1",
doi = "10.5005/jp-journals-10006-1669",
language = "English",
volume = "11",
pages = "100--102",
journal = "Journal of SAFOG",
issn = "0974-8938",
publisher = "Jaypee Brothers Medical Publishers (P) Ltd",
number = "2",

}

Maternal serum cancer antigen 125 : A marker of severity of Preeclampsia. / Geya, Gottipati; Supriya, Kantharaju.

In: Journal of SAFOG, Vol. 11, No. 2, 01.03.2019, p. 100-102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Maternal serum cancer antigen 125

T2 - A marker of severity of Preeclampsia

AU - Geya, Gottipati

AU - Supriya, Kantharaju

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Aim: The aim of this study is to study the levels of cancer antigen 125 (CA-125) in normal, preeclampsia, and gestational hypertension study groups and correlate with other parameters which mark the severity of the disease. Materials and methods: A cross-sectional study was conducted at a Tertiary Care Hospital, Mangaluru, India. A total of 165 subjects were divided into three study groups: preeclampsia, gestational hypertension, and normal pregnancy, and each group consisted of 55 subjects. CA-125 levels were measured in these study groups. Results: The mean value of CA-125 in the preeclampsia group was 56.7 IU/mL which was significantly higher compared with other two study groups. CA-125 was found to have a positive correlation with systolic blood pressure (BP) (r value = 0.4, p value = 0.001), diastolic BP (r value = 0.3, p value = 0.001), and uric acid (r value = 0.2, p value = 0.001) and also an association was observed between increasing CA-125 and proteinuria (p value = 0.001) oligohydramnios (p value = 0.001) fetal growth restriction (p value = 0.03) and onset of the disease (p value = 0.001). However, a negative correlation with platelets (r value = −0.14, p value = 0.06) and birth weight (r value = −0.113, p value = 0.15) was observed. Conclusion: CA-125 is a marker indicating increasing severity of the disease. It is a biochemical marker which can be used in the screening of preeclampsia. Further studies are needed for the evaluation of raising serial CA-125 levels as a marker of progression of the disease. Clinical significance: Hypertensive disorders of pregnancy are one of the most common causes of death due to pregnancy. CA-125 was proposed to be elevated in patients with hypertension due to chronic inflammation. Hence, CA-125 levels if used as a screening tool can estimate the severity of the disease and help clinicians in identifying women who are at risk for further complications and act accordingly.

AB - Aim: The aim of this study is to study the levels of cancer antigen 125 (CA-125) in normal, preeclampsia, and gestational hypertension study groups and correlate with other parameters which mark the severity of the disease. Materials and methods: A cross-sectional study was conducted at a Tertiary Care Hospital, Mangaluru, India. A total of 165 subjects were divided into three study groups: preeclampsia, gestational hypertension, and normal pregnancy, and each group consisted of 55 subjects. CA-125 levels were measured in these study groups. Results: The mean value of CA-125 in the preeclampsia group was 56.7 IU/mL which was significantly higher compared with other two study groups. CA-125 was found to have a positive correlation with systolic blood pressure (BP) (r value = 0.4, p value = 0.001), diastolic BP (r value = 0.3, p value = 0.001), and uric acid (r value = 0.2, p value = 0.001) and also an association was observed between increasing CA-125 and proteinuria (p value = 0.001) oligohydramnios (p value = 0.001) fetal growth restriction (p value = 0.03) and onset of the disease (p value = 0.001). However, a negative correlation with platelets (r value = −0.14, p value = 0.06) and birth weight (r value = −0.113, p value = 0.15) was observed. Conclusion: CA-125 is a marker indicating increasing severity of the disease. It is a biochemical marker which can be used in the screening of preeclampsia. Further studies are needed for the evaluation of raising serial CA-125 levels as a marker of progression of the disease. Clinical significance: Hypertensive disorders of pregnancy are one of the most common causes of death due to pregnancy. CA-125 was proposed to be elevated in patients with hypertension due to chronic inflammation. Hence, CA-125 levels if used as a screening tool can estimate the severity of the disease and help clinicians in identifying women who are at risk for further complications and act accordingly.

UR - http://www.scopus.com/inward/record.url?scp=85073545125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073545125&partnerID=8YFLogxK

U2 - 10.5005/jp-journals-10006-1669

DO - 10.5005/jp-journals-10006-1669

M3 - Article

AN - SCOPUS:85073545125

VL - 11

SP - 100

EP - 102

JO - Journal of SAFOG

JF - Journal of SAFOG

SN - 0974-8938

IS - 2

ER -